Contact
searchSearch
HMP Global
Login

Chronic Lymphocytic Leukemia Excellence Forum

Chronic Lymphocytic Leukemia
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Chelsea Renfro, PharmD
Interview
How Integrated Health System Pharmacies Enhance Treatment Adherence and Adverse Effect Management for CLL
03/21/2025
Houston Wyatt, PharmD; Chelsea E. Renfro, PharmD; Stephanie White, PharmD
This interview explores how integrated health system pharmacy services can improve medication adherence, persistence, and adverse effect management in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
This interview explores how integrated health system pharmacy services can improve medication adherence, persistence, and adverse effect management in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
This interview explores how...
03/21/2025
Journal of Clinical Pathways
Graf Headshot
Interview
The Future of Chronic Lymphocytic Leukemia Management with Targeted Therapies
03/17/2025
In this interview, an expert discusses the preclinical development and clinical impact of zanubrutinib in chronic lymphocytic leukemia, highlighting key findings from pivotal trials, comparisons with other therapies, and future research...
In this interview, an expert discusses the preclinical development and clinical impact of zanubrutinib in chronic lymphocytic leukemia, highlighting key findings from pivotal trials, comparisons with other therapies, and future research...
In this interview, an expert...
03/17/2025
Journal of Clinical Pathways
Fakhri
Interview
Overcoming CLL Treatment Challenges With Evolving Pathways and Targeted Therapies
02/13/2025
Bita Fakhri, MD, MPH
In this interview, Bita Fakhri, MD, MPH, discusses the evolving role of cellular therapies and novel targeted treatments in chronic lymphocytic leukemia, emphasizing the shift toward time-limited therapies to improve patient outcomes while...
In this interview, Bita Fakhri, MD, MPH, discusses the evolving role of cellular therapies and novel targeted treatments in chronic lymphocytic leukemia, emphasizing the shift toward time-limited therapies to improve patient outcomes while...
In this interview, Bita Fakhri,...
02/13/2025
Journal of Clinical Pathways
Hill Headshot
Interview
Optimizing Chronic Lymphocytic Leukemia Treatment Pathways With BTK and BCL-2 Inhibitors
02/05/2025
Brian T Hill, MD, PhD
In this interview, Dr Brian T Hill discusses advancements in chronic lymphocytic leukemia treatment, including the impact of targeted therapies like BTK and BCL-2 inhibitors, the role of genetic mutations in treatment decisions, and the...
In this interview, Dr Brian T Hill discusses advancements in chronic lymphocytic leukemia treatment, including the impact of targeted therapies like BTK and BCL-2 inhibitors, the role of genetic mutations in treatment decisions, and the...
In this interview, Dr Brian T...
02/05/2025
Journal of Clinical Pathways
Davids Headshot
Interview
Integrating Real-World Evidence and Clinical Trial Data in CLL Management
01/17/2025
Matthew S. Davids, MD, MMSc
In this interview, Matthew S. Davids, MD, MMSc, discusses the role of real-world evidence in chronic lymphocytic leukemia (CLL) management, treatment considerations for high-risk and comorbid patients, strategies for therapy discontinuation,...
In this interview, Matthew S. Davids, MD, MMSc, discusses the role of real-world evidence in chronic lymphocytic leukemia (CLL) management, treatment considerations for high-risk and comorbid patients, strategies for therapy discontinuation,...
In this interview, Matthew S....
01/17/2025
Journal of Clinical Pathways
Bhat Headshot
Interview
Novel Therapies and Their Impact on Treatment Pathways for Chronic Lymphocytic Leukemia
01/13/2025
Seema A. Bhat, MD
In this interview, Seema A. Bhat, MD, discusses the evolving treatment landscape for chronic lymphocytic leukemia, including strategies for treatment selection, sequencing, addressing diagnostic gaps, and exploring novel therapies to improve...
In this interview, Seema A. Bhat, MD, discusses the evolving treatment landscape for chronic lymphocytic leukemia, including strategies for treatment selection, sequencing, addressing diagnostic gaps, and exploring novel therapies to improve...
In this interview, Seema A....
01/13/2025
Journal of Clinical Pathways
John Burke, MD
Interview
Challenges in Initiating Venetoclax-Based Treatment for Patients With CLL
12/11/2024
John M. Burke, MD
John M. Burke, MD, Rocky Mountain Cancer Centers, provides an overview of his study that examined the barriers providers face in initiating venetoclax-based treatment for patients with chronic lymphocytic leukemia (CLL).
John M. Burke, MD, Rocky Mountain Cancer Centers, provides an overview of his study that examined the barriers providers face in initiating venetoclax-based treatment for patients with chronic lymphocytic leukemia (CLL).
John M. Burke, MD, Rocky...
12/11/2024
Journal of Clinical Pathways
Matthew Davids, MD
Videos
Factors Impacting the Development and Selection of Targeted Therapies for Patients With CLL
12/04/2024
Matthew S. Davids, MD, MMSc
Matthew S. Davids, MD, speaks about the latest targeted therapies for treating CLL, the challenges in developing these treatments, and how they are being used in the community oncology setting.
Matthew S. Davids, MD, speaks about the latest targeted therapies for treating CLL, the challenges in developing these treatments, and how they are being used in the community oncology setting.
Matthew S. Davids, MD, speaks...
12/04/2024
Journal of Clinical Pathways
Danielle Brander, MD
Videos
Chronic Lymphocytic Leukemia Treatment Trends in Community Oncology Settings
11/26/2024
Danielle M. Brander, MD
Danielle Brander, MD, highlights current trends in the community oncology setting for treating chronic lymphocytic leukemia (CLL) and how clinical pathways can assist oncologists with decision making for frontline therapy in CLL.
Danielle Brander, MD, highlights current trends in the community oncology setting for treating chronic lymphocytic leukemia (CLL) and how clinical pathways can assist oncologists with decision making for frontline therapy in CLL.
Danielle Brander, MD, highlights...
11/26/2024
Journal of Clinical Pathways
Danielle Brander, MD
Videos
Insights on BTK Inhibitors as Frontline Treatment for Chronic Lymphocytic Leukemia
11/22/2024
Danielle Brander, MD, discusses the latest National Comprehensive Cancer Network guidelines for chronic lymphocytic leukemia (CLL) and the efficacy of BTK inhibitors as monotherapy in the frontline treatment of CLL.
Danielle Brander, MD, discusses the latest National Comprehensive Cancer Network guidelines for chronic lymphocytic leukemia (CLL) and the efficacy of BTK inhibitors as monotherapy in the frontline treatment of CLL.
Danielle Brander, MD, discusses...
11/22/2024
Journal of Clinical Pathways
JCP January/February 2025

Current Issue

February 2025
Volume 11
Issue 1
Current Issue
Issue Archive

Special Reports

Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

Chelsea Renfro, PharmD
Interview
How Integrated Health System Pharmacies Enhance Treatment Adherence and Adverse Effect Management for CLL
03/21/2025
Houston Wyatt, PharmD; Chelsea E. Renfro, PharmD; Stephanie White, PharmD
This interview explores how integrated health system pharmacy services can improve medication adherence, persistence, and adverse effect management in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
This interview explores how integrated health system pharmacy services can improve medication adherence, persistence, and adverse effect management in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
This interview explores how...
03/21/2025
Journal of Clinical Pathways
Graf Headshot
Interview
The Future of Chronic Lymphocytic Leukemia Management with Targeted Therapies
03/17/2025
In this interview, an expert discusses the preclinical development and clinical impact of zanubrutinib in chronic lymphocytic leukemia, highlighting key findings from pivotal trials, comparisons with other therapies, and future research...
In this interview, an expert discusses the preclinical development and clinical impact of zanubrutinib in chronic lymphocytic leukemia, highlighting key findings from pivotal trials, comparisons with other therapies, and future research...
In this interview, an expert...
03/17/2025
Journal of Clinical Pathways
Fakhri
Interview
Overcoming CLL Treatment Challenges With Evolving Pathways and Targeted Therapies
02/13/2025
Bita Fakhri, MD, MPH
In this interview, Bita Fakhri, MD, MPH, discusses the evolving role of cellular therapies and novel targeted treatments in chronic lymphocytic leukemia, emphasizing the shift toward time-limited therapies to improve patient outcomes while...
In this interview, Bita Fakhri, MD, MPH, discusses the evolving role of cellular therapies and novel targeted treatments in chronic lymphocytic leukemia, emphasizing the shift toward time-limited therapies to improve patient outcomes while...
In this interview, Bita Fakhri,...
02/13/2025
Journal of Clinical Pathways
Hill Headshot
Interview
Optimizing Chronic Lymphocytic Leukemia Treatment Pathways With BTK and BCL-2 Inhibitors
02/05/2025
Brian T Hill, MD, PhD
In this interview, Dr Brian T Hill discusses advancements in chronic lymphocytic leukemia treatment, including the impact of targeted therapies like BTK and BCL-2 inhibitors, the role of genetic mutations in treatment decisions, and the...
In this interview, Dr Brian T Hill discusses advancements in chronic lymphocytic leukemia treatment, including the impact of targeted therapies like BTK and BCL-2 inhibitors, the role of genetic mutations in treatment decisions, and the...
In this interview, Dr Brian T...
02/05/2025
Journal of Clinical Pathways
Davids Headshot
Interview
Integrating Real-World Evidence and Clinical Trial Data in CLL Management
01/17/2025
Matthew S. Davids, MD, MMSc
In this interview, Matthew S. Davids, MD, MMSc, discusses the role of real-world evidence in chronic lymphocytic leukemia (CLL) management, treatment considerations for high-risk and comorbid patients, strategies for therapy discontinuation,...
In this interview, Matthew S. Davids, MD, MMSc, discusses the role of real-world evidence in chronic lymphocytic leukemia (CLL) management, treatment considerations for high-risk and comorbid patients, strategies for therapy discontinuation,...
In this interview, Matthew S....
01/17/2025
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use